

1. Elfgen C, Baumgartner S, Varga Z, Reeve K, **Tausch CJ**, Bjelic-Radisic V, Fleisch M, Güth U. Diagnostic delay in moderately/poorly differentiated breast cancer types. *Eur J Cancer Prev.* 2021 Apr 23.
2. Dubsky P, **Tausch C**. Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by Pfob et al. *Eur J Cancer.* 2021 Jan; 143:178-179.
3. Dubsky P, Pinker K, Cardoso F, Montagna G, Ritter M, Denkert C, Rubio IT, de Azambuja E, Curigliano G, Gentilini O, Gnant M, Günthert A, Hauser N, Heil J, Knauer M, Knotek-Roggenbauer M, Knox S, Kovacs T, Kuerer HM, Loibl S, Mannhart M, Meattini I, Penault-Llorca F, Radosevic-Robin N, Sager P, Španić T, Steyerova P, **Tausch C**, Peeters MTFDV, Weber WP, Cardoso MJ, Poortmans P. Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. *Lancet Oncol.* 2021 Jan;22(1):e18-e28.
4. Hovaguimian F, Braun J, Z'graggen BR, Schläpfer M, Dumrese C, Ewald C, Dedes KJ, Fink D, Rölli U, Seeberger M, **Tausch C**, Papassotiropoulos B, Puhan MA, Beck-Schimmer B. Anesthesia and Circulating Tumor Cells in Primary Breast Cancer Patients: A Randomized Controlled Trial. *Anesthesiology.* 2020 Sep;133(3):548-558.
5. Elfgen C, Güth U, Gruber G, Birrer S, Bjelic-Radisic V, Fleisch M, **Tausch CJ**. Breast-conserving surgery with intraoperative radiotherapy in recurrent breast cancer: the patient's perspective. *Breast Cancer.* 2020 Nov;27(6):1107-1113.
6. Müller M, Güth U, Varga Z, Reeve K, Bjelic-Radisic V, Fleisch M, **Tausch CJ**, Elfgen C. Clinical Imaging of the Heterogeneous Group of Triple-negative Breast Cancer. *Anticancer Res.* 2020Apr; 40(4):21252131.
7. Papassotiropoulos B, Güth U, Dubsky P, **Tausch C**. ASO Author Reflections: A Call for Surgeon Experience and Surgical Radicality to Prevent Residual Breast Tissue After Skin- and Nipple-Sparing Mastectomy. *Ann Surg Oncol.* 2019 Dec;26(Suppl 3):694-695.
8. Elfgen C, Papassotiropoulos B, Varga Z, Moskovszky L, Nap M, Güth U, Baege A, Amann E, Chiesa F, **Tausch C**. Correction to: Comparative analysis of confocal microscopy on fresh breast core needle biopsies and conventional histology. *Diagn Pathol.* 2019 Aug 8;14(1):87.
9. Elfgen C, Schmid SM, **Tausch CJ**, Montagna G, Güth U. Radiological Staging for Distant Metastases in Breast Cancer Patients with Confirmed Local and/or Locoregional Recurrence: How Useful are Current Guideline Recommendations? *Ann Surg Oncol.* 2019 Oct;26(11):3455-3461.
10. Elfgen C, Reeve K, Moskovszky L, Güth U, Bjelic-Radisic V, Fleisch M, **Tausch C**, Varga Z. Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes. *J Cancer Res Clin Oncol.* 2019 Aug;145(8):2051-2059.

11. Elfgen C, Papassotiropoulos B, Varga Z, Moskovszky L, Nap M, Güth U, Baege A, Amann E, Chiesa F, **Tausch C**. Comparative analysis of confocal microscopy on fresh breast core needle biopsies and conventional histology. *Diagn Pathol*. 2019 Jun 15;14(1):58.
12. Elfgen C, Varga Z, Reeve K, Moskovszky L, Bjelic-Radisic V, **Tausch C**, Güth U. The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay. *Breast Cancer Res Treat*. 2019 Aug;177(1):67-75.
13. Yip CH, Evans DG, Agarwal G, Buccimazza I, Kwong A, Morant R, Prakash I, Song CY, Taib NA, **Tausch C**, Ung O, Meterissian S. Global Disparities in Breast Cancer Genetics Testing, Counselling and Management. *World J Surg*. 2019 May;43(5):1264-1270.
14. Garcia-Etienne CA, Mansel RE, Tomatis M, Heil J, Biganzoli L, Ferrari A, Marotti L, Sgarella A, Ponti A; EUSOMA Working Group. Trends in axillary lymph node dissection for early-stage breast cancer in Europe: Impact of evidence on practice. *Breast*. 2019 Jun; 45: 89-96.
15. Papassotiropoulos B, Güth U, Chiesa F, Rageth C, Amann E, Baege A, Elfgen C, Varga Z, Moskovszky L, Endhardt K, Masser R, Tinguely M, Farhadi J, Lardi A, Dammann F, Diebold J, Li Q, Dubsky P, **Tausch C**. Prospective Evaluation of Residual Breast Tissue After Skin- or Nipple-Sparing Mastectomy: Results of the SKINI-Trial. *Ann Surg Oncol*. 2019 May;26(5):1254-1262.
16. Rageth CJ, Rubenov R, Bronz C, Dietrich D, **Tausch C**, Rodewald AK, Varga Z. Atypical ductal hyperplasia and the risk of underestimation: tissue sampling method, multifocality, and associated calcification significantly influence the diagnostic upgrade rate based on subsequent surgical specimens. *Breast Cancer*. 2019 Jul;26(4):452-458.
17. Rageth CJ, O'Flynn EAM, Pinker K, Kubik-Huch RA, Mundinger A, Decker T, **Tausch C**, Dammann F, Baltzer PA, Fallenberg EM, Foschini MP, Dellas S, Knauer M, Malhaire C, Sonnenschein M, Boos A, Morris E, Varga Z. Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). *Breast Cancer Res Treat*. 2019 Apr;174(2):279-296.
18. Weber WP, Haug M, Kurzeder C, Bjelic-Radisic V, Koller R, Reitsamer R, Fitzal F, Biazus J, Brenelli F, Urban C, Paulinelli RR, Blohmer JU, Heil J, Hoffmann J, Matrai Z, Catanuto G, Galimberti V, Gentilini O, Barry M, Hadar T, Allweis TM, Olisha O, Cardoso MJ, Gouveia PF, Rubio IT, de Boniface J, Svensjö T, Bucher S, Dubsky P, Farhadi J, Fehr MK, Fulco I, Ganz-Blättler U, Günthert A, Harder Y, Hauser N, Kappos EA, Knauer M, Landin J, Mechera R, Meani F, Montagna G, Ritter M, Saccilotto R, Schwab FD, Steffens D, **Tausch C**, Zeindler J, Soysal SD, Lohsiriwat V, Kovacs T, Tansley A, Wyld L, Romics L, El-Tamer M, Pusic AL, Sacchini V, Gnant M. Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy. *Breast Cancer Res Treat*. 2018 Dec;172(3):523-537.

19. Weber WP, **Tausch C**, Hayoz S, Fehr MK, Ribi K, Hawle H, Lupatsch JE, Matter-Walstra K, Chiesa F, Dedes KJ, Berclaz G, Lelièvre L, Hess T, Güth U, Pioch V, Sarlos D, Leo C, Canonica C, Gabriel N, Zeindler J, Cassoly E, Andrieu C, Soysal SD, Ruhstaller T, Fehr PM, Knauer M; Swiss Group for Clinical Cancer Research (SAKK). Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial. *Ann Surg Oncol*. 2018 Sep;25(9):2632-2640.
20. Baumgartner A, **Tausch C**, Hosch S, Papassotiropoulos B, Varga Z, Rageth C, Baege A. Ultrasound- based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients. *Breast*. 2018 Mar 5;39:19-23
21. Weber WP, Soysal SD, El-Tamer M, Sacchini V, Knauer M, **Tausch C**, Hauser N, Günthert A, Harder Y, Kappos EA, Schwab F, Fitzal F, Dubsy P, Bjelic-Radisic V, Reitsamer R, Koller R, Heil J, Hahn M, Blohmer JU, Hoffmann J, Solbach C, Heitmann C, Gerber B, Haug M, Kurzeder C. First international consensus conference on standardization of oncoplastic breast conserving surgery. *Breast Cancer Res Treat*. 2017 Aug;165(1):139-149.
22. Pestalozzi BC, **Tausch C**, Dedes KJ, Rochlitz C, Zimmermann S, von Moos R, Winterhalder R, Ruhstaller T, Mueller A, Buser K, Borner M, Novak U, Nussbaum CU, Seifert B, Bigler M, Bize V, Vilei SB, Rageth C, Aebi S; Swiss Group for Clinical Cancer Research (SAKK). Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10). *BMC Cancer*. 2017 Apr 13;17(1):265.
23. Rageth CJ, O'Flynn EAM, Comstock C, Kurtz C, Kubik R, Madjar H, Lepori D, Kampmann G, Mundinger A, Baege A, Decker T, Hosch S, **Tausch C**, Delaloye J, Morris E, Varga Z (2016): First international consensus conference on lesions of uncertain malignant potential in the breast (B3 lesions) *Breast Cancer Res Treat*
24. **Tausch C**, Baege A, Rageth C (2014) Mapping lymph nodes in cancer management - role of (99m)Tc- tilmanocept injection. *Onco Targets Ther* 7:1151-8
25. Schneeweiss A, Chia S, Hegg R, **Tausch C**, Deb R, Ratnayake J, McNally V, Ross G, Kiermaier A, Cortés J (2014): Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study; *Breast Cancer Res* 16: R73
26. **Tausch C**, Baege A, Dietrich D, Vergin I, Heuer H, Haldemann-Heusler R, Rageth C (2013): Can axillary reverse mapping avoid lymphedema in node positive breast cancer patients? *Eur J Surg Oncol* 39: 880- 886.

27. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, **Tausch C**, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J (2013): Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA); *Ann Oncol* 24: 2278-2284.
28. Varga Z, Sinn P, Fritzsche F, von Hochstetter A, Noske A, Schraml P, T **Tausch C**, Trojan A, Moch H (2013): Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer; *PLoS One* 8: e58483.
29. Trojan A, Vergopoulos A, Breitenstein U, **Tausch C**, Seifert B, Joechle W (2013) : CYP2D6 phenotype indicative for optimized antiestrogen efficacy associates with outcome in early breast cancer patients; *Cancer Chemother Pharmacol* 71: 301-306.
30. Dubsy PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, **Tausch C**, Stöger H, Haider K, Fitzal F, Singer CF, Stierer M, Sevela P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger GG, Greil R, Filipcic L, Gnant M (2012): Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group; *J Clin Oncol* 30: 722-728.
31. **Tausch C**, Taucher S, Dubsy P, Seifert M, Reitsamer R, Kwasny W, Jakesz R, Fitzal F, Filipcic L, Fridrik M, Greil R, Gnant M (2012): Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSCG); *Ann Surg Oncol* 19: 1808-1817.
32. **Tausch C**, Steger GG, Haid A, Jakesz R, Fridrik MA, Reitsamer R, Pöstlberger S, Lang A, Gnant M and Greil R on behalf of the ABCSCG (2011): Sentinel Node Biopsy after Primary Chemotherapy in Breast Cancer: A note of caution from Results of ABCSCG-14; *Breast J* 17: 230-238.
33. Rageth J, **Tausch C** (2009): Intramammarian flap reconstruction (IFR) technique in breast conserving surgery; *Breast* 18: 387-392.
34. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, **Tausch C**, Eidtmann H, Steger G, Kwasny W, Dubsy P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R, ABCSCG-12 Trial Investigators, Marth C (2009); Endocrine therapy plus zoledronic acid in premenopausal breast cancer; *N Engl J Med* 360: 679- 691.
35. Haid A, Kühn T, Goyal A, **Tausch C**, Peintinger F, Schrenk P, Gallowitsch H (2009): Sentinel Node Biopsy in Breast Cancer: Clinical Implication - Standard of Care - Future Prospects; *Breast Care* 4: 195-202.

36. **Tausch C**, Konstantiniuk P, Kugler F, Reitsamer R, Roka S, Postlberger S, Haid A (2008): Sentinel Lymph Node Biopsy After Preoperative Chemotherapy for Breast Cancer: Findings From the Austrian Sentinel Node Study Group. *Annals of Surgical Oncology* 15: 3378-3383.
37. Schrenk P, **Tausch C**, Wöfl S, Bogner S, Fridrik M, Wayand W (2008): Sentinel node mapping performed before preoperative chemotherapy may avoid axillary dissection in breast cancer patients with negative or micrometastatic sentinel nodes; *The American Journal of Surgery* 196: 176-183.
38. Schrenk P, **Tausch C**, Wayand W (2008): Lymphatic mapping in patients with primary or recurrent breast cancer following previous axillary surgery; *European Journal of Surgical Oncology* 34: 851-856.
39. Mlineritsch B, **Tausch C**, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R; on behalf of the Austrian Breast, Colorectal Cancer Study Group (ABCSCG) (2008): Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSCG-17); *Breast Cancer Research and Treatment* 112: 203-213.
40. Taucher S, Steger GG, Jakesz R, **Tausch C**, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Dubsky P, Poestlberger S, Tschmelitsch J, Samonigg H, Gnant M (2008): The potential risk of neoadjuvant chemotherapy in breast cancer patients – results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSCG-07); *Breast Cancer Research and Treatment* 112: 309-316.
41. Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, **Tausch C**, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H (2007): On behalf of the Austrian Breast and Colorectal Cancer Study Group. Extended Adjuvant Therapy With Anastrozole Among Postmenopausal Breast Cancer Patients: Results From the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a; *Journal of National Cancer Institute* 99: 1845-1853.
42. Steger GG, Galid A, Gnant M, Mlineritsch B, Lang A, **Tausch C**, Rudas M, Greil R, Wenzel C, Singer CF, Haid A, Postlberger S, Samonigg H, Luschin-Ebengreuth G, Kwasny W, Klug E, Kubista E, Menzel C, Jakesz R; ABCSCG-14 (2007): Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSCG-14; *J Clin Oncol* 25: 2012-2018.
43. Pötter R, Gnant M, Kwasny W, **Tausch C**, Handl-Zeller L, Pakisch B, Taucher S, Hammer J, Luschin-Ebengreuth G, Schmid M, Sedlmayer F, Stierer M, Reiner G, Kapp K, Hofbauer F, Rottenfusser A, Postlberger S, Haider K, Draxler W, Jakesz R; Austrian Breast and Colorectal Cancer Study Group (2007): Lumpectomy plus tamoxifen or anastrozole with or without whole

breast irradiation in women with favorable early breast cancer; *Int J Radiat Oncol Biol Phys* 68: 334-340.

44. **Tausch C**, Tschmelitsch J (2006): Minimal invasive surgery in surgical oncology; *Eur Surg* 38: 9-14.
45. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, **Tausch C**, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M on behalf of the ABCSG and the GABG (2005): Benefits of switching postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3224 women enrolled in ABCSG Trial 8 and ARNO 95 Trial; *Lancet* 366: 455-462.
46. Schrenk P, Konstantiniuk P, Wolf S, Bogner S, Roka S, Postlberger S, Selim U, Urbania A, Gebhard B, Rudas M, **Tausch Ch** (2005) Intraoperative frozen section examination of the sentinel lymph node in breast cancer. *Rozhl Chir* 84: 217-222.
47. **Tausch C**, Hintringer T, Kugler F, Schmidhammer C, Bauer M, Aufschneider M (2005): Breast conserving therapy by resection of the nipple-areolar complex for subareolar breast carcinoma; *Br J Surg* 92: 1368-1371.
48. Peters-Engl C, Konstantiniuk P, **Tausch C**, Haid A, Hoffmann B, Jagoutz-Herzlinger M, Kugler F, Redtenbacher S, Roka S, Schrenk P, Steinmassl D, Austrian Sentinel Node Biopsy Study Group (2004): The impact of preoperative breast biopsy on the risk of sentinel lymph node metastases: analysis of 2502 cases from the Austrian Sentinel Node Biopsy Study Group; *Br J Cancer* 91: 1782-1786.
49. Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M, **Tausch C**, Galid A, Steger G, Jakesz R; Austrian Breast and Colorectal Cancer Study Group (2003): Impact of pretreatment thrombocytosis on survival in primary breast cancer; *Thromb Haemost* 89: 1098-1106.
50. Jakesz R, Samonigg H, Gnant M, Kubista E, Depisch D, Kolb R, Mlineritsch B, Mischinger HJ, Menzel RC, Steindorfer P, Kwasny W, **Tausch C**, Stierer M, Taucher S, Seifert M, Hausmaninger H. For the Austrian Breast & Colorectal Cancer Study Group (2003): Significant increase in breast conservation in 16 years of trials conducted by the Austrian breast & colorectal cancer study group; *Ann Surg* 237: 556-564.
51. Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B, Steindorfer P, Kwasny W, Stierer M, **Tausch C**, Fridrik M, Wette V, Steger G, Hausmaninger H (2003): Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6; *J Clin Oncol* 21: 984-990.

52. Schrenk P, Wöfl S, **Tausch C**, Mauritz C, Konstantiniuk P, Haid A, Riegler-Keil M, Rudas M (2002): Sentinel node biopsy in patients with multicentric breast cancer using a subareolar injection technique; *Eur Surg* 34: 288-291.
53. Pichler-Gebhard B, Konstantiniuk P, **Tausch C**, Jörg L, Haid A, Schrenk P, Peters-Engl C, Roka S (2002): Factors affecting identification rate and positivity of the sentinel node in breast cancer in 1567 patients using blue dye and ^{99m}Tc-labelled colloid, based on a multicentre database project in Austria; *Eur Surg* 34: 272-276.
54. Haid A, Schrenk P, Roka S, **Tausch C**, Pichler-Gebhard B, Rudas M, Zimmermann G (2002): The importance of sentinel node biopsy in breast surgery; *Eur Surg* 34: 262 –266.
55. **Tausch C**, Konstantiniuk P, Jörg L, Dubsky P, Denison U, Haid A, Pichler-Gebhard B, Rudas M (2002): Sentinel node biopsy after preoperative chemotherapy in breast carcinoma – Is it safe? *Eur Surg* 34: 283-287.
56. Kwasny W, **Tausch C**, Haid A, Stierer M, Konstantiniuk P, Wayand U, Sevelda P (2002): Early experience with the advanced breast biopsy instrumentation system in a multicentre study; *Gynäkol Geburtshilfliche Rundsch* 42: 212-216.
57. Langsteger W, Jörg L, **Tausch C**, Heinisch M, Wieser B, Rechberger E, Panholzer PJ, Sega W, Aufschneider M (2002): The value of F-18 fluorodeoxyglucose in positron emission tomography diagnosis of breast carcinoma; *Wien Med Wochenschr* 152: 255-258.
58. Haid A, **Tausch C**, Lang A, Lutz J, Fritzsche H, Peschina W, Breitfellner G, Sega W, Aufschneider M, Sturn H, Zimmermann G (2001): Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma? *Cancer* 92: 1080-1084.
59. **Tausch C**, Konstantiniuk P, Haid A, Stierer M (2000): Early experience with the Advanced Breast Biopsy Instrumentation (ABBI®) System – a report of a multicenter study; *Acta Chirurgica Austriaca* 32: 1-5.
60. Jakesz R, Hausmaninger H, Samonigg H, Kubista E, Haider K, Mlineritsch B, Schmid M, **Tausch C**, Reiner G, Renner K, Stierer M, Jatzko G, Hofbauer F, Fridrik M, Schennach W, Sevelda P, Dadak C, Haid A, Scholz R, Lenzhofer P, Steindorfer P, Berger A, Mischinger HJ (1998): Therapy studies of the Austrian Breast Cancer Group (ABC); *Zentralbl Chirurg* 123: 28-32.